Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760010 | 0.90 | AR (0.47) | LMNASMN1; SMN2POLBPKMAR | |
| SCHEMBL6023759 | 0.82 | POLB (0.65) | POLBPKMARGAA | |
| SCHEMBL6022243 | 0.81 | AR (0.61) | LMNAPOLBPKMARALDH1A1 | |
| SCHEMBL6023623 | 0.81 | PKM (0.70) | POLBPKMARGAA | |
| SCHEMBL6022696 | 0.80 | GFER (0.55) | SMN1; SMN2POLBPKMARALDH1A1 | |
| SCHEMBL6022363 | 0.80 | FFAR1 (0.55) | SMN1; SMN2POLBPKMARTHRB | |
| SCHEMBL6022242 | 0.79 | ALDH1A1 (0.60) | LMNAPOLBPKMARALDH1A1 | |
| SCHEMBL6022578 | 0.79 | AR (0.52) | POLBPKMARGAA | |
| SCHEMBL6023096 | 0.79 | MAPT (0.62) | POLBPKMARTHRBGAA | |
| SCHEMBL6023208 | 0.79 | PKM (0.60) | LMNASMN1; SMN2POLBPKMAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | LMNA 4429/4885SMN1; SMN2 3892/4885POLB 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.